Challenges and Management of Acute Coronary Syndrome in Cancer Patients

Cancer and cardiovascular disease are the leading causes of mortality in the world. The prevalence of cardiovascular risk factors and coronary artery disease in cancer patients is elevated, and it is associated with high mortality. Several mechanisms, such as the proinflammatory and procoagulant states present in cancer patients, may contribute to these scenarios. Oncological therapy can predispose patients to acute thrombosis, accelerated atherosclerosis and coronary spasm. Treatment decisions must be individualized and based on the cancer history and balancing bleeding and thrombosis risks

cardiovascular manifestations in patients infected with the human immunodeficiency virus

n/

Diaphragmatic pacing stimulation in spinal cord injury: anesthetic and perioperative management

OBJECTIVE: The standard therapy for patients with high-level spinal cord injury is long-term mechanical ventilation through a tracheostomy. However, in some cases, this approach results in death or disability. The aim of this study is to highlight the anesthetics and perioperative aspects of patients undergoing insertion of a diaphragmatic pacemaker. METHODS: Five patients with quadriplegia following high cervical traumatic spinal cord injury and ventilator-dependent chronic respiratory failure were implanted with a laparoscopic diaphragmatic pacemaker after preoperative assessments of their phrenic nerve function and diaphragm contractility through transcutaneous nerve stimulation. ClinicalTrials.gov: NCT01385384. RESULTS: The diaphragmatic pacemaker placement was successful in all of the patients. Two patients presented with capnothorax during the perioperative period, which resolved without consequences. After six months, three patients achieved continuous use of the diaphragm pacing system, and one patient could be removed from mechanical ventilation for more than 4 hours per day. CONCLUSIONS: The implantation of a diaphragmatic phrenic system is a new and safe technique with potential to improve the quality of life of patients who are dependent on mechanical ventilation because of spinal cord injuries. Appropriate indication and adequate perioperative care are fundamental to achieving better results

Blood transfusion in cardiac surgery is a risk factor for increased hospital length of stay in adult patients

Abstract\ud \ud \ud \ud Background\ud \ud Allogeneic red blood cell (RBC) transfusion has been proposed as a negative indicator of quality in cardiac surgery. Hospital length of stay (LOS) may be a surrogate of poor outcome in transfused patients.\ud \ud \ud \ud Methods\ud \ud Data from 502 patients included in Transfusion Requirements After Cardiac Surgery (TRACS) study were analyzed to assess the relationship between RBC transfusion and hospital LOS in patients undergoing cardiac surgery and enrolled in the TRACS study.\ud \ud \ud \ud Results\ud \ud According to the status of RBC transfusion, patients were categorized into the following three groups: 1) 199 patients (40%) who did not receive RBC, 2) 241 patients (48%) who received 3 RBC units or fewer (low transfusion requirement group), and 3) 62 patients (12%) who received more than 3 RBC units (high transfusion requirement group). In a multivariable Cox proportional hazards model, the following factors were predictive of a prolonged hospital length of stay: age higher than 65 years, EuroSCORE, valvular surgery, combined procedure, LVEF lower than 40% and RBC transfusion of > 3 units.\ud \ud \ud \ud Conclusion\ud \ud RBC transfusion is an independent risk factor for increased LOS in patients undergoing cardiac surgery. This finding highlights the adequacy of a restrictive transfusion therapy in patients undergoing cardiac surgery.\ud \ud \ud \ud Trial registration\ud \ud Clinicaltrials.gov identifier: http://NCT01021631.The authors would like to thank Suelly Zeferino and Lígia Camara for their assistance with data extraction. There was no external funding source for this research.This work was supported by the Department of Anaesthesiology, InCor, University of Sao Paulo

The Heart and COVID-19: What Cardiologists Need to Know

In face of the pandemic of the novel coronavirus disease 2019 (COVID-19), the management of patients with cardiovascular risk factors and/or disease is challenging. The cardiovascular complications evidenced in patients with COVID-19 derive from several mechanisms, ranging from direct viral injury to complications secondary to the inflammatory and thrombotic responses to the infection. The proper care of patients with COVID-19 requires special attention to the cardiovascular system aimed at better outcomes

Liberal or restrictive strategy of red blood cell transfusion in cardiac surgery: a randomized controlled clinical trial

Introdução: O objetivo deste estudo foi avaliar o efeito de uma estratégia restritiva de transfusão de hemácias comparada a uma estratégia liberal na evolução clínica de pacientes submetidos à cirurgia cardíaca com circulação extracorpórea. Métodos: Estudo prospectivo, randomizado, e controlado. Foram randomizados 512 pacientes para uma estratégia liberal de transfusão (hematócrito 30%) ou restritiva (hematócrito 24%). Resultados: Os pacientes apresentaram idade média de 60,7 ± 12,5 anos no grupo liberal e 58,6 ± 12,5 anos no grupo restritivo. Em ambos, houve predomínio de pacientes com fração de ejeção normal, mas 13% dos pacientes do grupo liberal e 15% do grupo restritivo apresentavam fração de ejeção abaixo de 40%. A mortalidade ou a morbidade grave em 30 dias foi semelhante nos dois grupos (10% na estratégia liberal e 11% na estratégia restritiva, P=0,518). Não houve diferença entre os grupos em relação às taxas de complicações secundárias. A média da concentração de hemoglobina foi 10,5 0,9 g/dL no grupo liberal e 9,1 1,2 gdL no grupo restritivo (P<0,001). No grupo liberal, 198 pacientes (78%) receberam transfusão de hemácias, e no grupo restritivo 118 pacientes (47%). Independente da estratégia utilizada, o número de transfusão de hemácias foi fator preditor independente para a ocorrência de complicações clínicas graves ou morte em 30 dias (OR=1,21; IC 95%=1,1-1,4, P= 0,002). Conclusão: A estratégia restritiva de transfusão foi tão segura quanto à estratégia liberal em pacientes submetidos à cirurgia cardíaca com circulação extracorpórea. Cada unidade de concentrado de hemácias administrada foi associada a aumento de 1,2 vezes no risco de mortalidade em 30 diasIntroduction: The aim of this study was to evaluate whether a restrictive strategy of red blood cells transfusion is as safe as a liberal one with respect to clinical outcomes. Methods: In this prospective, randomized, controlled clinical trial we randomly assigned 512 patients after cardiac surgery to a liberal strategy of transfusion (to maintain a hematocrit at least at 30%) or to a restrictive one (to maintain a hematocrit at least at 24%). Results: The mean age of patients was 60.7 ± 12.5 year-old in liberal group vs. 58.6 ± 12.5 year-old in restrictive group. In both groups, most patients had normal left ventricular function, but 13% of patients in the liberal group and 15% in the restrictive one presented ejection fraction of less than 40%. The primary end-point - a composite endpoint of 30 day all cause mortality or severe morbidity was similar between groups (10% in the liberal-strategy group vs. 11% in the restrictive-strategy group) (P=0.518). Also, there were no differences between groups with respect to the rates of other complications. Hemoglobin concentrations were maintained at a level of 10.5 ± 0.9 g/dL in the liberal group and 9.1 ± 1.2 g/dL in the restrictive group (P<0.001). A total of 198 patients (78%) in the liberal group and 118 patients (47%) in the restrictive group received a blood transfusion (P<0.001). Independently of the strategy group, the number of transfused RBC units was an independent risk factor for the occurrence of several clinical complications or death at 30 days (HR = 1.21; CI 95%=1.1-1.4, P=0.002). Conclusions: A restrictive transfusion strategy was as safe as a liberal strategy in patients undergoing cardiac surgery. For each RBC unit transfused, transfusion was independently associated with a 1.2-fold higher risk of death at 30 day

What's new in transfusion policies?

SCOPUS: ar.jinfo:eu-repo/semantics/publishe